drugset / Trial / NCT01432223
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy in terms of the pathological complete response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based regimen followed by Nab-paclitaxel and Trastuzumab in patients with HER2 positive operable breast cancer.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-11
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |